Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 67,741 Shares

Key Points

• Neumora Therapeutics insider Daljit Singh Aurora sold 67,741 shares at an average price of $1.51, generating $102,288.91 and reducing his position by 58.15% to 48,750 shares. The filing follows several additional sales between August 17 and August 21.
• NMRA shares rose $0.12 to $1.63, while the company reported a quarterly loss of $0.23 per share—slightly better than the $0.24 consensus estimate. The stock remains below its 200-day moving average of $2.10 and has traded between $0.83 and $3.65 over the past year.
• Analyst sentiment remains a Moderate Buy, with an average price target of $6.57, although several firms recently reduced their targets. Institutional investors own 47.65% of the company, with multiple large funds increasing their holdings.

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Daljit Singh Aurora sold 67,741 shares of the business's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $1.51, for a total transaction of $102,288.91. Following the transaction, the insider owned 48,750 shares in the company, valued at $73,612.50. This trade represents a 58.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daljit Singh Aurora also recently made the following trade(s):

• On Thursday, August 20th, Daljit Singh Aurora sold 66,711 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.51, for a total transaction of $100,733.61.
• On Friday, August 21st, Daljit Singh Aurora sold 21,055 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.60, for a total value of $33,688.00.
• On Friday, August 21st, Daljit Singh Aurora sold 20,553 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.59, for a total value of $32,679.27.
• On Wednesday, August 19th, Daljit Singh Aurora sold 30,918 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.65, for a total transaction of $51,014.70.
• On Wednesday, August 19th, Daljit Singh Aurora sold 31,000 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.65, for a total transaction of $51,150.00.
• On Monday, August 17th, Daljit Singh Aurora sold 55,016 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.50, for a total value of $82,524.00.
• On Monday, August 17th, Daljit Singh Aurora sold 91,690 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total transaction of $137,535.00.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,987 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.59, for a total value of $55,629.33.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,162 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.58, for a total transaction of $53,975.96.

Neumora Therapeutics Stock Performance

Shares of NMRA stock traded up $0.12 during trading hours on Friday, reaching $1.63. 498,604 shares of the company's stock were exchanged, compared to its average volume of 765,644. The company has a debt-to-equity ratio of 1.19, a quick ratio of 5.09 and a current ratio of 4.50. Neumora Therapeutics, Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $3.65. The stock's 50 day moving average is $1.60 and its 200-day moving average is $2.10.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01. On average, analysts expect that Neumora Therapeutics, Inc. will post -0.85 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Invesco Ltd. raised its stake in shares of Neumora Therapeutics by 151.1% in the 1st quarter. Invesco Ltd. now owns 123,655 shares of the company's stock worth $124,000 after buying an additional 74,406 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of Neumora Therapeutics during the 1st quarter valued at about $463,000. Russell Investments Group Ltd. boosted its holdings in Neumora Therapeutics by 2,898.1% in the second quarter. Russell Investments Group Ltd. now owns 73,812 shares of the company's stock worth $56,000 after purchasing an additional 71,350 shares in the last quarter. Marshall Wace LLP acquired a new position in Neumora Therapeutics during the second quarter valued at approximately $183,000. Finally, Federated Hermes Inc. increased its position in Neumora Therapeutics by 10.4% in the 2nd quarter. Federated Hermes Inc. now owns 314,119 shares of the company's stock worth $230,000 after buying an additional 29,543 shares during the period. 47.65% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada cut their price target on shares of Neumora Therapeutics from $7.00 to $5.00 and set an "outperform" rating for the company in a report on Monday, July 13th. Needham & Company LLC decreased their price target on Neumora Therapeutics from $8.00 to $5.00 and set a "buy" rating for the company in a report on Tuesday, June 16th. Wall Street Zen raised Neumora Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 15th. Weiss Ratings cut shares of Neumora Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, August 14th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Neumora Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $6.57.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora's product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source